📜 iter-4360dd15-0015.log
13058 bytes
# Iter-0015 mission=4360dd15
# goal: 找到让人类长生不老的方法
# time: 2026-04-25T23:03:43
# focus_node: root :: 找到让人类长生不老的方法
========== TRANSCRIPT ==========
→ call task_view({"max_depth":6})
【tool:task_view】
{"ok": true, "tree": "GOAL: 找到让人类长生不老的方法\n· [✓ done ] root: 找到让人类长生不老的方法\n├─ [✓ done ] n1: 建立 marker 锚定后的局部交换判定框架 ← 已完成 marker 锚定后的局部交换判定框架：固定 μ 锚点、排除触及 μ 的交换、用 greedy witness span 压缩候选窗口，并在触及 wit\n│ ├─ [✓ done ] n5: 规范化 witness：固定 μ 锚点并限制一次交换的位置 ← 完成 witness 规范化：确认固定 μ 锚点时必须排除触碰 μ 的交换，并用 greedy witness span 将允许交换压缩到局部窗口内；小规模穷举\n│ │ ├─ [✓ done ] n9: 证伪一次交换跨越 μ 的规范化可能性 ← 用穷举验证并归纳出结构性事实：任何触及唯一 marker μ 的相邻交换都会使 μ 的位置改变 1，因此在固定 μ 位置的 witness 规范化里，不存在“跨\n│ │ ├─ [✓ done ] n10: 把单侧交换位置压缩为可判定窗口 ← 证明并穷举验证：对左块 greedy witness 的最左/最右嵌入位置 p1..pk，窗口外相邻交换不会改变最大前缀消耗 k，因此允许交换位置可压缩为 [p\n│ │ └─ [✓ done ] n11: 沉淀 witness 规范形模板 ← 沉淀出 witness 规范形模板：固定 μ 锚点、排除触及 μ 的交换、以 greedy witness span 限定局部窗口，并用左块最大前缀消耗 k 作\n│ ├─ [✓ done ] n6: 建立单侧切分判定接口：把可行性压成存在切分点 k ← 把固定 μ 锚点后的可行性压成了单侧切分接口：左块只通过最大前缀消耗长度 k 传递，且 k 由 X 决定、与 Y 无关。\n│ ├─ [✓ done ] n7: 刻画交换不依赖右侧的充分条件 ← 验证了一个可复用充分条件：若一次相邻交换不改变对任意 S 的左块最大前缀消耗 k，则对所有右侧 Y 的可行性判定保持不变；并用穷举检查了 small-case \n│ ├─ [✓ done ] n8: 沉淀可复用的验证模板与失败边界 ← 找到验证模板的失败边界：任意 witness span 不够，必须用 greedy witness span；给出反例 X=abb, S=ba，窗口外交换仍可改\n│ ├─ [✓ done ] n12: 探索两次相邻交换下 greedy witness span 的局部性边界 ← 在二元字母表、长度 n<=8 的穷举中，未找到“两个相邻交换都发生在原始 greedy witness span 之外却改变 k”的反例；这给出了多交换局部性边\n│ ├─ [✓ done ] n13: 把 marker 锚定后的局部交换判定落实为可执行的 O(n)~O(n log n) 检查流程 ← 完成了一个可执行的局部交换检查流程：先算 k，再用 greedy witness span 的局部闭包限制候选交换；对二元字母表、|X|<=8、|S|<=8 的\n│ ├─ [✓ done ] n14: 证伪 greedy witne
→ call search_memory({"limit":8,"mission_only":false,"query":"aging immunology bottleneck inflammaging cGAS STING NLRP3 interferon myeloid"})
→ call search_memory({"limit":8,"mission_only":false,"query":"IL-1 MyD88 complement thymic involution naive repertoire aging immunology"})
→ call search_memory({"limit":8,"mission_only":false,"query":"immune inflammation longevity bottleneck upstream candidate reversible aging"})
【tool:search_memory】
{"ok": true, "results": [{"title": "cGAS-STING is an upstream inflammaging amplifier, but not yet a universal longevity bottleneck", "tags": "fact lesson aging immunology principle", "mission": "", "modified": "20260425143829000", "preview": "!! cGAS-STING is an upstream inflammaging amplifier, but not yet a universal longevity bottleneck ''结论'': cGAS-STING 可以被视为比单纯局部炎症读出更上游的炎症-衰老放大器；PNAS 2025 原始研究显示在复制衰老、衰老细胞和早衰成纤维细胞中，STING 呈现非经典定位并且 cGAS/STING 依赖的炎症程序被激活，说明其与 cellular/organismal aging 存在因果连接。但截至目前，公开证据仍主要停留在机制与健康表型，缺少直接寿命终点；同时，STING/cGAS 缺失还会带来脂质与胆固醇稳态代价。因此，在长寿靶点评估里，它应被保留为高潜力候选，而不是直接升级为 universal longevity bottleneck。"}, {"title": "cGAS-STING is a strong but context-dependent aging node, not yet a universal longevity bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425145335000", "preview": "!! cGAS-STING is a strong but context-dependent aging node, not yet a universal longevity bottleneck ''结论'': cGAS-STING 更像是一个在特定组织、应激背景和疾病阶段下会放大的炎症/免疫节点，而不是目前可直接当作通用长寿瓶颈的默认假设。 ''审稿式判断'': # 它值得优先审视，因为它可能解释部分 inflammaging、DNA damage response 与免疫激活的耦合。 # 但不能把“强相关”直接升级成“通用瓶颈”，更不能默认它对所有组织、所有年龄阶段、所有干预方向都成立。 # 若没有明确的情境限定、因果链路和干预可重复性，它应被视为 //context-dependent amplifier//，而不是 universal bottleneck。"}, {"title": "NLRP3 is a strong aging node but still not clearly a universal longevity bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425143408000", "preview": "!! NLRP3 is a strong aging node but still not
【tool:search_memory】
{"ok": true, "results": [{"title": "IL-1/MyD88 outranks TNF/IL-6 as an upstream screening candidate, but not as a universal bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425145846000", "preview": "!! IL-1 / MyD88 should be ranked above TNF/IL-6 as an upstream inflammatory screening candidate, but still below universal longevity bottlenecks ''结论'': When screening immune/inflammation axes for a longevity bottleneck, IL-1/MyD88 deserves higher priority than TNF or IL-6 because it sits more upstream in the hematopoietic inflammaging chain (microbiome-driven HSC decline, emergency myelopoiesis, "}, {"title": "Immune longevity candidate ranking: thymic involution first, readouts later", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425041227000", "preview": "!! 免疫长寿候选的优先级：thymic involution > naive T-cell loss > trained immunity / inflammaging / innate senescence ''结论'': 在筛选免疫/炎症相关的高杠杆长寿入口时，优先级应按“可逆上游性 + 功能性恢复 + 跨读出证据”排序。 # ''thymic involution''：如果原始研究能在胸腺层面被上游干预逆转，并恢复外周 naive T-cell pool 与功能免疫读出，就应视为可干预瓶颈。 # ''naive T-cell loss''：更像 thymic 下降的下游读出，单独作为入口的上游性不足。 # ''inflammaging''：默认按 context-dependent readout 处理，不能直接当作通用上游总瓶颈。 # ''trained immunity''：可"}, {"title": "Thymic involution can be experimentally reversed to restore naive T-cell output in aged mice", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425040945000", "preview": "!! Thymic involution is a reve
【tool:search_memory】
{"ok": true, "results": [{"title": "trained immunity is a functional defense amplifier, not a higher-priority longevity bottleneck than thymic source restoration", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425130412000", "preview": "!! trained immunity is a functional defense amplifier, not a higher-priority longevity bottleneck than thymic source restoration ''结论'': β-glucan-induced trained immunity can enhance host resistance to infection in aged mice (18–20 mo old), but the public evidence currently remains at infection resistance / innate immune readout level; it does not yet establish lifespan or broad healthspan benefit"}, {"title": "IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425132624000", "preview": "!! IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck ''结论'': Among the screened immune/inflammation nodes, IL-11 currently ranks highest because it crosses the strongest available threshold: direct mouse healthspan + lifespan benefit, not merely local inflammation readouts. ''Key evidence'': # [[PMID 39020175]] / Nature 2024: anti-IL-11 fro"}, {"title": "Thymic source restoration is a strong immune upstream entry, but not yet a universal longevity bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modi
→ call pubmed_search({"limit":10,"query":"IL-11 aging lifespan healthspan mouse Nature 2024 anti-IL-11"})
→ call pubmed_search({"limit":10,"query":"IL-11 inflammation aging immune axis bone metabolism regeneration"})
→ call web_search({"limit":8,"query":"IL-11 aging lifespan healthspan anti-IL-11 Nature 2024"})
【tool:pubmed_search】
{"ok": true, "query": "IL-11 aging lifespan healthspan mouse Nature 2024 anti-IL-11", "results": [{"pmid": "39020175", "title": "Inhibition of IL-11 signalling extends mammalian healthspan and lifespan.", "source": "Nature", "pubdate": "2024 Aug", "authors": ["Widjaja AA", "Lim WW", "Viswanathan S", "Chothani S", "Corden B", "Dasan CM", "Goh JWT", "Lim R"], "url": "https://pubmed.ncbi.nlm.nih.gov/39020175/"}]}
【tool:pubmed_search】
{"ok": true, "query": "IL-11 inflammation aging immune axis bone metabolism regeneration", "results": []}
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
→ call task_add({"parent_id":"n82","rationale":"IL-11 已有直接鼠类寿命/健康寿命证据，可能把免疫/炎症筛选从‘上游候选’推进到‘当前第一优先级’；需要单独审计其与 IL-1/MyD88、thymic involution 等候选的相对位置。","title":"审计 IL-11 是否应升格为免疫/炎症轴中的当前第一候选"})
【tool:task_add】
{"ok": true, "id": "n121", "parent": "n82", "title": "审计 IL-11 是否应升格为免疫/炎症轴中的当前第一候选", "status": "pending"}
→ call write_note({"tags":["fact","lesson","principle","aging","immunology"],"text":"!! IL-11 currently ranks above other screened immune/inflammation axes because it has direct mammalian healthspan/lifespan evidence ''结论'': 在已筛选的免疫/炎症轴中，IL-11 目前应排在最高优先级，原因不是它“最像炎症因子”，而是它跨过了更强的证据门槛：直接鼠类健康寿命/寿命改善。 ''关键证据'': # PMID 39020175 / Nature 2024: ''Inhibition of IL-11 signalling extends mammalian healthspan and lifespan.'' )
【tool:write_note】
{"ok": true, "path": "/root/Sisyphus/wiki/tiddlers/IL-11_currently_ranks_above_other_screened_immune_inflammation_axes_because_it_has_direct_mammalian_healthspan_lifespan_.tid", "title": "IL-11 currently ranks above other screened immune/inflammation axes because it has direct mammalian healthspan/lifespan evidence"}
→ call task_done({"id":"n82","result":"完成免疫/炎症瓶颈候选的排序升级：IL-11 以直接鼠类健康寿命/寿命证据暂列第一优先级，位于 IL-1/MyD88、thymic involution、cGAS-STING、NLRP3、补体与 TNF/IL-6 之前，但仍未被证实为通用长寿瓶颈。"})
【tool:task_done】
{"ok": true, "id": "n82", "status": "done", "next_focus": "root"}
【assistant】
本轮已把免疫/炎症候选排序向前推进：IL-11 因为有 PMID 39020175 / Nature 2024 的直接 mammalian healthspan/lifespan 证据，暂列当前第一优先级；但它仍未跨过“通用长寿瓶颈”的门槛。
<NEXT_FOCUS>当前可转向 root 下的下一条高杠杆长寿主线，或开始审计 IL-11 的通用性与安全边界</NEXT_FOCUS>
========== REFLECTION ==========
{
"progress": "本轮把免疫/炎症轴的优先级向前推进：IL-11 因具备直接鼠类健康寿命/寿命延长证据，被暂列为当前第一候选，但仍未被证明是通用长寿瓶颈。",
"failure": "未能把 IL-11 从“高优先级候选”进一步证实为可跨组织、可长期安全干预的通用机制，而且网络不可用限制了外部证据补强。",
"lesson": {
"worthy": false,
"title": "",
"tags": [],
"text": ""
},
"next_focus": "审计 IL-11 的寿命获益是否主要来自免疫/炎症重编程，并排除其效果被骨代谢或其他系统性副作用所主导。"
}